Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MMP3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA579683
Description
Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 μg/mL. Positive Control - WB: Human Placenta Tissue, U20S whole cell, HELA whole cell, PANC whole cell, COLO320 whole cell.
MMP3 (stromelysin-1) belongs to the peptidase M10A subfamily. It is secreted in its pro-protein form, and is activated by extracellular proteinase cleavage. MMP3 is capable of binding to zinc and calcium ions, and has metallo-endopeptidase activity. The active enzyme degrades collagen, gelatin, fibronectin, and laminin. It is involved in normal cellular processes such as wound repair and tissue remodeling. Mutations in the gene can result in coronary heart disease 6.
Specifications
MMP3 | |
Polyclonal | |
Unconjugated | |
MMP3 | |
CHDS6; EC 3.4.24.17; EMS-2; matrix metallo protease; matrix metallopeptidase 3; matrix metallopeptidase 3 (stromelysin 1, progelatinase); matrix metalloproteinase 3; matrix metalloproteinase 3 (stromelysin 1, progelatinase); matrix metalloproteinase 3 precursor; matrix metalloproteinase-3; metalloproteinase 3 receptor; MMP; MMP10; MMP3; MMP-3; MMP-3 protein; MMPs; progelatinase; proteoglycanase; SL-1; SLN1; SLN-1; STMY; STMY1; Str1; STR-1; stromelysin; stromelysin 1; Stromelysin1; stromelysin-1; Transin1; Transin-1 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
4314 | |
-20°C | |
Lyophilized |
Western Blot | |
500 μg/mL | |
PBS with 5mg BSA and 0.05mg sodium azide | |
P08254 | |
MMP3 | |
A synthetic peptide corresponding to a sequence at the C-terminal of human MMP3 (410-439aa RFDEKRNSMEPGFPKQIAEDFPGIDSKIDA). | |
100 μg | |
Primary | |
Human | |
Antibody | |
IgG |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction